Stock Events

Stock Events

Pacific Edge Limited 

NZ$0.18
8
+NZ$0+0% Friday 05:00

Statistics

Day High
0.19
Day Low
0.19
52W High
0.24
52W Low
0.08
Volume
115,387
Avg. Volume
800,365
Mkt Cap
179.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-137.03%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
43.69MRevenue
-59.87MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PEB.NZ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
EXACT Sciences
EXAS
Mkt Cap20.03B
Exact Sciences Corporation offers cancer screening and diagnostic tests, competing directly in the cancer diagnostics market similar to Pacific Edge.
Guardant Health
GH
Mkt Cap10.31B
Guardant Health provides liquid biopsy tests for cancer diagnostics, directly competing with Pacific Edge's cancer detection technologies.
Fulgent Genetics
FLGT
Mkt Cap450.66M
Fulgent Genetics, Inc. offers genetic testing to detect cancer, competing in the genomic and molecular diagnostic space like Pacific Edge.
Myriad Genetics
MYGN
Mkt Cap406.76M
Myriad Genetics, Inc. focuses on molecular diagnostic tests that assess the risk of developing cancer, similar to Pacific Edge's diagnostic products.
Qiagen NV
QGEN
Mkt Cap8.43B
QIAGEN N.V. provides sample to insight solutions including cancer diagnostics, competing in the same field as Pacific Edge.
NuCana
NCNA
Mkt Cap8.2M
NuCana plc develops technology to enhance chemotherapy agents, indirectly competing with Pacific Edge by offering alternative cancer treatment solutions.

About

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence. In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
Show more...
CEO
ISIN
NZPEBE0002S1

Listings

NZ
NZ
PEB.NZ
F
DE
CY3.F
AU
AU
PEB.AU
OTC Link
US
PFGTF

0 Comments

Share your thoughts

FAQ

What is Pacific Edge Limited stock price today?▼
The current price of PEB.NZ is NZ$0.18 NZD — it has increased by +0% in the past 24 hours. Watch Pacific Edge Limited stock price performance more closely on the chart.
What is Pacific Edge Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pacific Edge Limited stocks are traded under the ticker PEB.NZ.
Is Pacific Edge Limited stock price growing?▼
PEB.NZ stock has fallen by -8.33% compared to the previous week, the month change is a -2.76% fall, over the last year Pacific Edge Limited has showed a +44.26% increase.
What is Pacific Edge Limited market cap?▼
Today Pacific Edge Limited has the market capitalization of 179.9M
What is Pacific Edge Limited revenue for the last year?▼
Pacific Edge Limited revenue for the last year amounts to 43.69M NZD.
What is Pacific Edge Limited net income for the last year?▼
PEB.NZ net income for the last year is -59.87M NZD.
In which sector is Pacific Edge Limited located?▼
Pacific Edge Limited operates in the Other sector.
When did Pacific Edge Limited complete a stock split?▼
Pacific Edge Limited has not had any recent stock splits.